US equities
|
MU
$938.07
▼-1.59%
NVDA
$223.94
▼-2.00%
SPCX
$153.33
▼-2.05%
AAPL
$345.99
▲+1.38%
META
$743.99
▼-2.43%
TSLA
$367.47
▼-2.07%
SNDK
$1,435.06
▼-3.19%
AMD
$582.53
▼-3.80%
MU
$938.07
▼-1.59%
NVDA
$223.94
▼-2.00%
SPCX
$153.33
▼-2.05%
AAPL
$345.99
▲+1.38%
META
$743.99
▼-2.43%
TSLA
$367.47
▼-2.07%
SNDK
$1,435.06
▼-3.19%
AMD
$582.53
▼-3.80%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
10x Genomics, Inc. - Common Stock
(NQ:
TXG
)
72.69
+0.90 (+1.25%)
Delayed Quote
Updated: 10:31 AM EDT, Oct 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 10x Genomics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
↗
October 12, 2026
Forget the "Magnificent Seven" in favor of the "Tremendous Three"?
Via
The Motley Fool
Why Are 10x Genomics (TXG) Shares Soaring Today
October 09, 2026
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 6.1% in the morning session after Bank of America raised its price target on the st...
Via
StockStory
Topics
Artificial Intelligence
10x Genomics (TXG) Stock Is Up, What You Need To Know
September 28, 2026
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.8% in the afternoon session after Argus analyst John Eade initiated coverage on t...
Via
StockStory
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know
September 23, 2026
What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid S...
Via
StockStory
Q2 Rundown: 10x Genomics (NASDAQ:TXG) Vs Other Life Sciences Tools & Services Stocks
September 21, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
Topics
Artificial Intelligence
3 Russell 2000 Stocks That Fall Short
September 17, 2026
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
Via
StockStory
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
September 11, 2026
What Happened? A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity ma...
Via
StockStory
3 Inflated Stocks with Open Questions
September 04, 2026
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u...
Via
StockStory
3 Small-Cap Stocks with Open Questions
August 25, 2026
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
Via
StockStory
10x Genomics (TXG) Q2 2026 Earnings Call Transcript
↗
August 14, 2026
Atera demand drives spatial transition as booked orders exceed 2026 targets.
Via
The Motley Fool
Topics
Earnings
Intellectual Property
World Trade
5 Revealing Analyst Questions From 10x Genomics’s Q2 Earnings Call
August 13, 2026
10x Genomics’ second quarter results came in above Wall Street’s expectations for both revenue and profitability, yet the market responded negatively. Manage...
Via
StockStory
Topics
Earnings
1 High-Flying Stock to Own for Decades and 2 We Question
August 12, 2026
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...
Via
StockStory
10x Genomics Q2 Earnings Call Highlights
↗
August 07, 2026
10x Genomics (NASDAQ:TXG) reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara. Excluding non-recurring settlement...
Via
MarketBeat
Topics
Earnings
TXG Q2 Deep Dive: Atera Launch Signals Transition as Spatial Market Shifts
August 07, 2026
Biotech company 10x Genomics (NASDAQ:TXG) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 12.6% year on year to $15...
Via
StockStory
Topics
Artificial Intelligence
1 Unpopular Stock That Deserves Some Love and 2 That Underwhelm
August 07, 2026
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Via
StockStory
10x Genomics’s (NASDAQ:TXG) Q2 CY2026: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations
August 06, 2026
Biotech company 10x Genomics (NASDAQ:TXG) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 12.6% year on year to $151 ...
Via
StockStory
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect
August 04, 2026
Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results this Thursday after market close. Here’s what to expect. 10x Genomics beat anal...
Via
StockStory
1 Surging Stock with Solid Fundamentals and 2 Facing Headwinds
July 31, 2026
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...
Via
StockStory
1 Healthcare Stock to Keep an Eye On and 2 We Avoid
July 28, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...
Via
StockStory
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
July 24, 2026
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HC...
Via
StockStory
1 Cash-Producing Stock with Exciting Potential and 2 Facing Challenges
July 20, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via
StockStory
3 Russell 2000 Stocks We Steer Clear Of
July 16, 2026
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...
Via
StockStory
3 Cash-Heavy Stocks We Find Risky
July 09, 2026
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
Via
StockStory
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)
July 07, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
Topics
Artificial Intelligence
Economy
1 Unprofitable Stock on Our Watchlist and 2 We Brush Off
July 06, 2026
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
Via
StockStory
Stocks making big moves this week: Qualcomm, Accenture, 10x Genomics, Seagate, and Lattice Semiconductor
June 26, 2026
Check out the companies making headlines this week: Qualcomm (NASDAQ:QCOM): Wireless chipmaker Qualcomm (NASDAQ:QCOM) fell by 4.7% on Wednesday after a lever...
Via
StockStory
Topics
Artificial Intelligence
Economy
Why Is 10x Genomics (TXG) Stock Soaring Today
June 24, 2026
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 6.8% in the morning session after Barclays boosted its price target to $40 per shar...
Via
StockStory
10x Genomics (TXG): Buy, Sell, or Hold Post Q1 Earnings?
June 19, 2026
The past six months have been a windfall for 10x Genomics’s shareholders. The company’s stock price has jumped 116%, setting a new 52-week high of $34.69 per...
Via
StockStory
Topics
Supply Chain
3 Small-Cap Stocks with Questionable Fundamentals
June 11, 2026
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
Via
StockStory
10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.
↗
June 01, 2026
10x Genomics, a leader in single cell and spatial genomics tools, reported a notable insider sale amid ongoing sector innovation.
Via
The Motley Fool
Topics
Regulatory Compliance
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
